Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Valkema MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, Biermann K, Lagarde SM, Bennink RJ, Schreurs WMJ, Roef MJ, Hobbelink MGG, Janssen MJR, Graven LH, van Lanschot JJB, Valkema R. Valkema MJ, et al. Among authors: schreurs wmj. J Nucl Med. 2019 Nov;60(11):1553-1559. doi: 10.2967/jnumed.118.224196. Epub 2019 Mar 15. J Nucl Med. 2019. PMID: 30877177 Free article. Clinical Trial.
External ultrasonography of the neck does not add diagnostic value to integrated positron emission tomography-computed tomography (PET-CT) scanning in the diagnosis of cervical lymph node metastases in patients with esophageal carcinoma.
Blom RL, Vliegen RF, Schreurs WM, Belgers HJ, Stohr I, Oostenbrug LE, Sosef MN. Blom RL, et al. Dis Esophagus. 2012 Aug;25(6):555-9. doi: 10.1111/j.1442-2050.2011.01289.x. Epub 2011 Dec 9. Dis Esophagus. 2012. PMID: 22150869
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
Noordman BJ, Wijnhoven BPL, Lagarde SM, Boonstra JJ, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, Spaander MCW, Valkema R, van der Zaag ES, Steyerberg EW, van Lanschot JJB; SANO-study group. Noordman BJ, et al. BMC Cancer. 2018 Feb 6;18(1):142. doi: 10.1186/s12885-018-4034-1. BMC Cancer. 2018. PMID: 29409469 Free PMC article.
Surveillance of Clinically Complete Responders Using Serial 18F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy.
Valkema MJ, van der Wilk BJ, Eyck BM, Wijnhoven BPL, Spaander MCW, Doukas M, Lagarde SM, Schreurs WMJ, Roef MJ, van Lanschot JJB, Valkema R. Valkema MJ, et al. Among authors: schreurs wmj. J Nucl Med. 2021 Apr;62(4):486-492. doi: 10.2967/jnumed.120.247981. Epub 2020 Sep 4. J Nucl Med. 2021. PMID: 32887759 Free PMC article.
External validation of 18 F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy.
Valkema MJ, Beukinga RJ, Chatterjee A, Woodruff HC, van Klaveren D, Noordzij W, Valkema R, Bennink RJ, Roef MJ, Schreurs W, Doukas M, Lagarde SM, Wijnhoven BPL, Lambin P, Plukker JTM, van Lanschot JJB. Valkema MJ, et al. Nucl Med Commun. 2023 Aug 1;44(8):709-718. doi: 10.1097/MNM.0000000000001707. Epub 2023 May 3. Nucl Med Commun. 2023. PMID: 37132272 Free PMC article.
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Larue RT, Van De Voorde L, Berbée M, van Elmpt WJ, Dubois LJ, Panth KM, Peeters SG, Claessens A, Schreurs WM, Nap M, Warmerdam FA, Erdkamp FL, Sosef MN, Lambin P. Larue RT, et al. BMC Cancer. 2016 Aug 17;16:644. doi: 10.1186/s12885-016-2709-z. BMC Cancer. 2016. PMID: 27535748 Free PMC article. Clinical Trial.
16 results